Ask AI
ProCE Banner Activity

ATOMIC: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab in Patients With Stage III Deficient DNA Mismatch Repair Colon Cancer

Conference Coverage
Slideset

In patients with stage III dMMR colon cancer, use of adjuvant mFOLFOX6 with atezolizumab significantly reduced the risk of disease progression or death vs mFOLFOX6 alone.

Released: June 04, 2025

Expiration: December 03, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group